Powerski Maciej Janusz, Erxleben Christoph, Scheurig-Münkler Christian, Geisel Dominik, Heimann Uwe, Hamm Bernd, Gebauer Bernhard
Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Leipziger Strasse 44, 39120 Magdeburg, Germany.
Department of Radiology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Eur J Radiol. 2015 Feb;84(2):201-7. doi: 10.1016/j.ejrad.2014.11.004. Epub 2014 Nov 13.
In patients undergoing transarterial radioembolization (RE) of malignant liver tumors, hepatopulmonary shunts (HPS) can lead to nontarget irradiation of the lungs. This study aims at analyzing the HPS fraction in relation to liver volume, tumor volume, tumor-to-liver volume ratio, tumor vascularity, type of tumor, and portal vein occlusion.
In the presented retrospective study the percentage HPS fraction was calculated from SPECT/CT after infusion of Tc-99m macroaggregated albumin (Tc-99m MAA) into the proper hepatic artery of 233 patients evaluated for RE.
HPS fractions correlate very weakly with liver volume (r=0.303), tumor volume (r=0.345), and tumor-to-liver volume ratio (r=0.340). Tumors with strong contrast enhancement (HPSmedian(range)=11.7%(46.3%); n=73) have significantly larger shunt fractions than tumors with little enhancement (HPS=8.3%(16.4%); n=61; p<0.001). Colorectal cancer metastases (HPS=10.6%(28.6%); n=68) and hepatocellular cancers (HPS=11.7%(39.4%); n=63) have significantly larger HPS fractions than metastases from breast cancer (HPS=7.4%(16.7%); n=40; p=0.012 and p=0.001). Patients with compression (HPS=13.9%(43.7%); n=33) or tumor thrombosis (HPS=15.8% (31.2%); n=33) of a major portal vein branch have significantly higher degrees of shunting than patients with normal portal vein perfusion (HPS=8.1% (47.0%); n=167; both p<0.001). The shunt fraction is largest in patients with HCC and thrombosis or occlusion of a major portal vein branch (HPS=16.6% (31.0%); n=32).
The degree of hepatopulmonary shunting depends on the type of liver tumor, tumor vascularity, and portal vein perfusion. There is little to no correlation of HPS with liver volume, tumor volume, or tumor-to-liver volume ratio.
在接受恶性肝肿瘤经动脉放射性栓塞(RE)治疗的患者中,肝肺分流(HPS)可导致肺部非靶向性照射。本研究旨在分析HPS分数与肝脏体积、肿瘤体积、肿瘤与肝脏体积比、肿瘤血管生成、肿瘤类型和门静脉闭塞之间的关系。
在本回顾性研究中,对233例接受RE评估的患者,经肝固有动脉注入99m锝标记的大颗粒白蛋白(Tc-99m MAA)后,通过SPECT/CT计算HPS分数百分比。
HPS分数与肝脏体积(r=0.303)、肿瘤体积(r=0.345)和肿瘤与肝脏体积比(r=0.340)的相关性非常弱。对比增强明显的肿瘤(HPS中位数(范围)=11.7%(46.3%);n=73)的分流分数显著高于增强不明显的肿瘤(HPS=8.3%(16.4%);n=61;p<0.001)。结直肠癌转移灶(HPS=10.6%(28.6%);n=68)和肝细胞癌(HPS=11.7%(39.4%);n=63)的HPS分数显著高于乳腺癌转移灶(HPS=7.4%(16.7%);n=40;p=0.012和p=0.001)。主要门静脉分支受压(HPS=13.9%(43.7%);n=33)或肿瘤血栓形成(HPS=15.8%(31.2%);n=33)的患者的分流程度显著高于门静脉灌注正常的患者(HPS=8.1%(47.0%);n=167;p均<0.001)。肝癌合并主要门静脉分支血栓形成或闭塞的患者分流分数最大(HPS=16.6%(31.0%);n=32)。
肝肺分流程度取决于肝肿瘤类型、肿瘤血管生成和门静脉灌注。HPS与肝脏体积、肿瘤体积或肿瘤与肝脏体积比几乎没有相关性。